Brümmendorf, Tim H.

Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood

Rufer, N., Brümmendorf, T. H., Kolvraa, S., Bischoff, C., Christensen, K., Wadsworth, L., Schulzer, M., & Lansdorp, P. M. (1999) · The Journal of Experimental Medicine

Telomeres, Telomerase, and SenescenceHematopoietic Stem Cell Transplantation

Cited by 709

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

Hehlmann, R., Voskanyan, A., Lauseker, M., Pfirrmann, M., Kalmanti, L., Rinaldetti, S., Kohlbrenner, K., Haferlach, C., Schlegelberger, B., Fabarius, A., et al. (2020) · Leukemia

Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Cited by 91

JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality

Rao, T. N., Hansen, N., Stetka, J., Luque Paz, D., Kalmer, M., Hilfiker, J., Endele, M., Ahmed, N., Kubovcakova, L., Rybarikova, M., et al. (2021) · Blood

Myeloproliferative Neoplasms: Diagnosis and TreatmentHematopoietic Stem Cell Transplantation

Cited by 72

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia

Schönfeld, L., Rinke, J., Hinze, A., Nagel, S. N., Schäfer, V., Schenk, T., Fabisch, C., Brümmendorf, T. H., Burchert, A., le Coutre, P., et al. (2022) · Leukemia

Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Cited by 57

Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias

Kota, V., Brümmendorf, T. H., Gambacorti-Passerini, C., Lipton, J. H., Kim, D.-W., An, F., Leip, E., Crescenzo, R. J., Ferdinand, R., & Cortes, J. E. (2021) · Leukemia Research

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 25

Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial

Hochhaus, A., Burchert, A., Saussele, S., Baerlocher, G. M., Mayer, J., Brümmendorf, T. H., La Rosée, P., Heim, D., Krause, S. W., le Coutre, P., et al. (2023) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 21

Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy

Rolles, B., Gorgulho, J., Tometten, M., Roderburg, C., Vieri, M., Abels, A., Vucur, M., Heymann, F., Tacke, F., Brümmendorf, T. H., et al. (2021) · Frontiers in Oncology

Telomeres, Telomerase, and SenescenceCancer Immunotherapy and Biomarkers

Cited by 12

ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry

Kohlbrenner, K., Galuschek, N., Fabarius, A., Reiser, M., Fenchel, K., Esseling, E., Göhler, T., Kühn, R.-B., Depenbusch, R., Talah Azeh, I., et al. (2023) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 1